Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

• Status: Completed
• Trial end date: 2002-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Hereditary hemorrhagic telangiectasia (HHT, Rendu-Osler-Weber Syndrome) is associated with frequent nosebleeds in the majority of cases. Several reports in the literature support the use of antifibrinolytics like Tranexamic acid to reduce nosebleeds. The objectives of the study are to test if Tranexamic acid taken orally can

1. improve anemia (lead to an increased hemoglobin level)

2. reduce nosebleeds.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Saarland
• Collaborators: Baxter Healthcare Corporation; Pharmacia GmbH, Erlangen, Germany
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria:

• hereditary hemorrhagic telangiectasia with nosebleeds and desire to be treated.

Exclusion Criteria:

• pregnant,

• minor,

• had an increased risk of thrombotic events (history or signs of cerebrovascular events, cardiac arrhythmias, biochemically increased coagulation parameters),

• renal insufficiency,

• a history of massive hematuria or defects of color vision.